Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis
The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.
1. A peptide wherein the peptide sequence comprises
(SEQ ID NO: 32)
VECTT R EKEVLA S LDKAAFLTQLHS;
wherein R and S are stapled.
2. The peptide according to claim 1 , wherein R is 2-(7-octenyl)arginine and S is 2-(4-pentenyl)serine.
3. A pharmaceutical composition comprising a peptide according to claim 1 .
4. A method of treating a disease selected from the group consisting of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma and fibrosis comprising the administration of a peptide according to claim 1 , or a pharmaceutical composition thereof, to a subject in need of treatment.
5. The method according to claim 4 , wherein the fibrosis is a liver fibrosis, liver cirrhosis, renal fibrosis, cardiac fibrosis, atrial fibrosis, endomyocardial fibrosis, old myocardial infarction, pulmonary fibrosis, cystic fibrosis, radio-induced lung fibrosis, vascular fibrosis, arterial fibrosis, brain fibrosis, myelofibrosis, arthrofibrosis, intestinal fibrosis, peritoneal fibrosis, retroperitoneal fibrosis or skin fibrosis.
6. A pharmaceutical composition comprising a peptide according to claim 2 .
7. A method of treating a disease selected from the group consisting of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma and fibrosis comprising the administration of a peptide according to claim 2 , or a pharmaceutical composition thereof, to a subject in need of treatment.
8. The method according to claim 7 , wherein the fibrosis is a liver fibrosis, liver cirrhosis, renal fibrosis, cardiac fibrosis, atrial fibrosis, endomyocardial fibrosis, old myocardial infarction, pulmonary fibrosis, cystic fibrosis, radio-induced lung fibrosis, vascular fibrosis, arterial fibrosis, brain fibrosis, myelofibrosis, arthrofibrosis, intestinal fibrosis, peritoneal fibrosis, retroperitoneal fibrosis or skin fibrosis.